Body fat

Key facts

Body fat distribution—especially visceral (abdominal) versus subcutaneous depots—drives chronic inflammation and metabolic risk as much as total weight.

What is a healthy body fat percentage for men?

ACSM/ACE reference ranges: ~10–20% ‘fit,’ 21–24% acceptable, ≥25% higher risk (athletes and older adults differ).

What is a healthy body fat percentage for women?

ACSM/ACE reference ranges: ~18–28% ‘fit,’ 29–32% acceptable, ≥33% higher risk.

Why does visceral fat matter more than BMI alone?

Visceral adipose drains into the portal vein, exposing the liver to inflammatory cytokines and free fatty acids—raising diabetes and cardiovascular risk even at normal BMI (‘normal weight obesity’).

Total body fat % — reference ranges

ACSM/ACE reference ranges for adults: men ~10–20% ‘fit,’ 21–24% acceptable, ≥25% higher risk; women ~18–28% ‘fit,’ 29–32% acceptable, ≥33% higher risk (athletes and older adults differ). From DEXA, BIA, or calipers—whole-body only, not depot-specific. ‘Normal weight obesity’ (normal BMI, high body-fat %) appears in ~20–30% of normal-BMI adults and often pairs with elevated visceral fat. Pair with waist/WHR/WtHR from the depot sections below—not instead of them. Log body fat % and view your trend graph

Visceral fat

Visceral fat wraps abdominal organs and drains into the portal vein; waist ≥94 cm (men) or ≥80 cm (women) by IDF criteria flags elevated metabolic risk even at normal BMI.

Inflammatory signaling

Expanded visceral adipocytes and infiltrating macrophages produce IL-6, TNF-α, and CRP. Leptin rises while adiponectin falls, impairing insulin sensitivity. This low-grade elevation predicts cardiovascular events, frailty, and cognitive decline independent of acute infection.

Metabolic & organ stress

Portal fatty-acid overload promotes hepatic steatosis, dyslipidemia, and ectopic fat deposition in muscle and pancreas. Visceral adiposity correlates with hypertension, type 2 diabetes, NAFLD, and sleep apnea. Reducing visceral depots often improves labs before scale weight changes dramatically.

Waist circumference — evidence & cutoffs

Waist tracks central adiposity better than BMI alone. IDF criteria: ≥94 cm (37 in) European men, ≥80 cm (31.5 in) European women; US NCEP ATP III: ≥102 cm (40 in) men, ≥88 cm (35 in) women. NHANES and Framingham cohorts show rising diabetes and CVD above these bands even at ‘normal’ BMI. Measure at the iliac crest at end-expiration.

Waist-to-height ratio (WtHR) — data

Ashwell & Gibson (2012) meta-analysis (~300,000 adults): WtHR <0.5 flags increased cardiometabolic risk more consistently than BMI across ethnic groups. WtHR 0.5–0.6 ≈1.5–2× higher diabetes/CVD risk vs <0.5; ≥0.6 is high risk in most guidelines. Example: 178 cm (5 ft 10 in) → waist under 89 cm (35 in).

How much visceral fat is ‘too much’?

On CT/MRI at L4–L5, visceral fat area ≥100 cm² (Asian cohorts) to ~130–150 cm² (Western ‘high’) marks elevated metabolic risk; ~>2 kg visceral mass on MRI associates with marked insulin resistance. If waist or WtHR exceed thresholds above, treat visceral burden as actionable regardless of scale weight. DEXA android/gynoid ratio >1.0 or top-quartile visceral estimate for age/sex also flags concern.

Training & diet

Resistance training preserves lean mass; Zone 2 aerobic work (~60–70% max HR, 150+ min/week) improves fat oxidation—combined programs shrink visceral depots more reliably than diet alone; waist often drops before BMI. Caloric deficit with protein ≈1.2–1.6 g/kg/day, fiber, and limiting excess alcohol, fructose, and ultra-processed foods reduce hepatic and visceral accumulation.

Visceral fat is a modifiable upstream driver of the Chronic inflammation hallmark—see sections above for evidence-backed waist, WtHR, and imaging cutoffs.

Subcutaneous fat

Subcutaneous fat sits under the skin and is less inflammatory per kilogram than visceral fat, but waist-to-hip ratio (WHR) >0.90 in men or >0.85 in women signals elevated cardiovascular risk.

Storage & endocrine role

Subcutaneous adipocytes store triglycerides and secrete leptin and adiponectin. Unlike visceral fat, they do not drain directly into the portal vein, so hepatic spillover per unit mass is lower.

Waist-to-hip ratio (WHR) — evidence & cutoffs

WHR = waist ÷ hip at widest gluteal circumference. WHO abdominal-obesity thresholds: >0.90 men, >0.85 women. INTERHEART (~27,000 cases) and Prospective Studies Collaboration: WHR predicts MI and all-cause mortality independently of BMI—each +0.1 WHR ≈20–30% higher CVD risk in adjusted models. Gluteofemoral (hip/thigh) dominance → lower WHR and better lipid/glucose profiles; abdominal subcutaneous fat is intermediate risk vs visceral.

How much is alright?

No fixed optimal subcutaneous mass—use total body fat % for whole-body ranges and WHR (above) for shape. WtHR cutoffs live on Visceral fat. Rising waist despite stable weight signals overflow into central depots; DEXA limb fat or skinfolds track shifts over time.

Inflammatory profile & loss dynamics

Fewer crown-like macrophage structures and lower IL-6/TNF-α than visceral depots at comparable size. Subcutaneous fat often mobilizes first in deficit (face, limbs) while waist may lag—scale weight can fall before central slimming. Deficit plus resistance training limits muscle loss.

Cell biology & spot reduction

See Fat types & cell biology for adipocyte hypertrophy vs hyperplasia, brown/white/beige fat, and why spot reduction fails while local muscle hypertrophy works.

Subcutaneous fat is the default storage depot; WHR and overflow into visceral/ectopic sites—not limb fat alone—drive residual risk.

Fat types & cell biology

White adipose tissue (WAT) stores energy; brown and beige fat dissipate heat; ectopic fat in liver and muscle drives insulin resistance—spot reduction of fat does not work.

White adipose tissue (WAT)

Dominant adult form—unilocular lipid, stores triglycerides, secretes leptin, adiponectin, and cytokines when expanded. Most subcutaneous and visceral fat is WAT.

Brown adipose tissue (BAT)

Multilocular lipid, UCP1-rich mitochondria—non-shivering thermogenesis. Adults retain supraclavicular depots (~3–10% show cold-activated BAT on PET/MRI). Cold exposure (~16–19 °C) may add ~100–300 kcal/day in BAT-positive people—modest, not a primary weight-loss lever.

Beige / brite adipocytes

Thermogenic cells inducible within white depots via cold, catecholamines, or myokines. Human weight impact is smaller than caloric balance; aerobic activity and adequate sleep support favorable signaling.

Ectopic & other depots

Fat in liver, pancreas, heart, or muscle fibers links to insulin resistance regardless of BMI. Bone-marrow and pericardial fat behave like visceral fat in inflammatory output. Reduction requires systemic deficit and activity—not local tricks.

Adipocyte hypertrophy vs hyperplasia

Hypertrophy enlarges existing cells; hyperplasia adds new ones when subcutaneous capacity saturates. Hypertrophy-heavy profiles correlate with more inflammation and insulin resistance in biopsies. Regain after loss often re-hypertrophies remaining cells—stable weight maintenance matters.

Spot reduction vs local muscle growth

Fat mobilization is systemic—controlled trials show no preferential loss over trained vs untrained sites (e.g. Ramírez-Campillo et al.). Liposuction/cryolipolysis remove subcutaneous cells cosmetically but do not fix visceral/ectopic load without lifestyle change. Muscle adapts locally: resistance training hypertrophies worked fibers; satellite cells support growth. Strategy: deficit for global fat loss, overload for muscle where you want it.

Misunderstanding fat types fuels ineffective tactics—spot gadgets, ignoring visceral risk, or skipping resistance training.